1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04395742

Acronym

TMX COVID

Enrollment

Registered

2020-05-20

Start date

2020-05-31

Completion date

2020-12-31

Last updated

2020-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Disease 2019

Brief summary

This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX). Trimethylxanthine is the active molecule present in coffee. Due to the lack of etiologic treatments and considering interest about old treatments as an avenue for research, we conducted a comparative study aiming to evaluate the effect of 1,3,7-trimethylxanthine on COVID-19 infected patients. This is actually a study about methodology. The objective of this study is therefore not to demonstrate the effect of the substance on the disease but the importance of a rigorous methodology in scientific research. This project is called Method and Teaching of Scientific Studies.

Interventions

OTHERData collection

Only data collection

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Inclusion criteria

* Age \> 18, * No Trimethylxanthine contraindications (defined as allergy, previous reported secondary effects), * Infectious Disease Unit admission.

Exclusion criteria

* Secondary effects about Trimethylxanthine, * Refuse to participate

Design outcomes

Primary

Measure	Time frame	Description
Comparison of vital status	6 days	the patient clinical status at day 6 after hospital admission, defined as alive, or dead.

Secondary

Measure	Time frame	Description
Comparaison of duration of hospital stay	6 days	—
Comparaison of severity	6 days	Evaluated by National Early Warning Score from 0 to 20, 20 being the worst score, with a high risk of death.
Comparaison of secondary effects (adverse events that needed disruption of treatment (anemia, tachycardia, osteoporosis) : secondary effects of coffee).	6 days	with
Comparaison of use of antibiotics	14 days after hospital admission.	—

Contacts

Primary ContactAlexandre BLEIBTREU

alexandre.bleibtreu@aphp.fr142163303

Backup ContactPaul ROBLOT

paul.roblot@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026